ESC Premium Access

Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH)

Congress Presentation

About the speaker

Doctor Hossam Fayed

University College London, London (United Kingdom of Great Britain & Northern Ireland)
1 presentation
0 follower

5 more presentations in this session

Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension: a new elephant in the cathlab

Speaker: Doctor A. Kempny (London, GB)


Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension

Speaker: Doctor M. D'Alto (Naples, IT)


Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

Speaker: Professor S. Rosenkranz (Cologne, DE)


Waitlist outcomes for Eisenmengers patients listed for bilateral sequential lung transplant or heart-lung transplant

Speaker: Doctor K. Kearney (Sydney, AU)


Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension

Speaker: Doctor K. Takeuchi (Tokyo, JP)


Access the full session

New concepts in pulmonary hypertension

Speakers: Doctor H. Fayed, Doctor A. Kempny, Doctor M. D'Alto, Professor S. Rosenkranz, Doctor K. Kearney...

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

Live Q&A.

29 August 2021

Open Access

Mode of intervention in mitral regurgitation.

28 August 2021

Open Access

Long-term outcomes in PAH: Optimised approach to achieve the best outcomes.

27 August 2021

ESC 365 is supported by

logo Novo Nordisk